Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.

Azadeh NasrazadaniJuan Luis Gomez MartiKate LathropAlvaro RestrepoSzu-Yun LeuGajanan BhatAdam M Brufsky

Published in: Breast cancer research and treatment (2024)

Poziotinib demonstrated evidence of clinical activity in patients with pre-treated HER2-positive advanced breast cancer, although high levels of toxicity may preclude further studies at this time.

Keyphrases

oxidative stress
case control
replacement therapy